Search Results

BioForest

Sound Pharmaceuticals’ IND Involving Cochlear Implantation Allowed by the FDA

Sound Pharmaceuticals (SPI) is pleased to announce that it has received FDA notification that its Investigational New Drug Application (IND) may proceed involving SPI-1005 treatment and cochlear implantation (CI).

May 20, 2024

·

3 min read

Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies

Sensorion announces that promising new data and analysis results from the SENS-401 following cochlear implantation Phase 2a clinical study will be presented at the 17th International Conference on Cochlear Implants and Other Implantable Technologies taking place on July 10-13, 2024, in Vancouver, Canada.

June 20, 2024

·

5 min read

Cochlear receives FDA clearance to lower the age for the Osia System to 5-years-old

Cochlear Limited (ASX: COH) obtained U.S. Food and Drug Administration (FDA) clearance to lower the age of the Cochlear™ Osia System from 12 years-old to 5-years-old for children with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).

April 19, 2024

·

4 min read

Drug Development

Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation

Sensorion announces the recruitment of the last patient in its Phase 2a clinical trial of SENS-401 for residual hearing preservation in adult patients following cochlear implantation.

February 1, 2024

·

5 min read

Cochlear™ Osia® System becomes industry’s first active bone conduction system to enable MRI at 3 Tesla

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, introduces its next generation Cochlear™ Osia® System with the ability to have an MRI at 3.0 T, designed to improve hearing outcomes for people with conductive hearing loss, mixed hearing loss and single-sided sensorineural deafness (SSD).

August 18, 2023

·

5 min read

BioMidwest

New Clinical Publication Reports First Three Patients in Early Feasibility Trial for Envoy Medical’s Fully Implanted Cochlear Device

A recent clinical publication in the Journal of Clinical Medicine (JCM) highlighted early surgical experience with Envoy Medical®, Inc.’s (“Envoy Medical”) (NASDAQ: “COCH”) investigational Acclaim® fully implantable cochlear implant.

October 19, 2023

·

8 min read

Business

Advanced Bionics Announces New President and Management Board Member

Advanced Bionics is pleased to announce the appointment of Alistair Simpson as its new president, and Group Vice President (GVP) for cochlear implants on the Sonova Management Board, effective immediately.

July 1, 2024

·

3 min read

FDA

FDA approves Cochlear’s Nucleus 8 Sound Processor, smaller, smarter, better connected cochlear implant technology

Cochlear Limited (ASX: COH), the global leader in implantable hearing solutions, receives U.S. Food and Drug Administration (FDA) approval for the Cochlear™ Nucleus® 8 Sound Processor.

November 1, 2022

·

7 min read

BioMidwest

Envoy Medical Early Feasibility Study of Breakthrough Fully Implanted Cochlear Implant Now Underway

Envoy Medical® Corporation announced the first patient has been enrolled and implanted in the Acclaim® Cochlear Implant early feasibility study at Mayo Clinic in Rochester, Minn.

November 1, 2022

·

4 min read

MED-EL Presents: World Cochlear Implant Day 2023 - Over 45 years of major technological advances that enhance hearing and quality of life

MED-EL, a leader in implantable hearing solutions, celebrates together with everyone living with and benefiting from cochlear implants.

February 24, 2023

·

5 min read